Terms: = Kidney tumors AND FOXL2, BPES, 668, ENSG00000183770, P58012, PFRK, POF3, PINTO, BPES1 AND Treatment
17 results:
1. Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.
Tomita Y; Motzer RJ; Choueiri TK; Rini BI; Miyake H; Oya M; Albiges L; Aizawa M; Umeyama Y; Wang J; di Pietro A; Schmidinger M
ESMO Open; 2023 Dec; 8(6):102034. PubMed ID: 37866029
[TBL] [Abstract] [Full Text] [Related]
2. The risk of acute kidney injury in colorectal cancer survivors: an english population-based matched cohort study.
Andresen K; Carreira H; Strongman H; McDonald HI; Benitez-Majano S; Mansfield KE; Nitsch D; Tomlinson LA; Bhaskaran K
BMC Cancer; 2023 Sep; 23(1):839. PubMed ID: 37679679
[TBL] [Abstract] [Full Text] [Related]
3. Association Between Oncology Clinical Pathway Utilization and Toxicity and Cost Outcomes in Patients With Metastatic Solid tumors.
Liu Y; Mullangi S; Debono D; Chen X; Pham T; Fisch MJ; Gordon AS; Hershman DL
JCO Oncol Pract; 2023 Sep; 19(9):731-740. PubMed ID: 37384847
[TBL] [Abstract] [Full Text] [Related]
4. Segmental ureterectomy for high-risk ureteral carcinoma: a preliminary report.
Wei W; Liu J; Wang L; Duan X; Ding D
BMC Urol; 2023 Jun; 23(1):103. PubMed ID: 37277741
[TBL] [Abstract] [Full Text] [Related]
5. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Brown JE; Royle KL; Gregory W; Ralph C; Maraveyas A; Din O; Eisen T; Nathan P; Powles T; Griffiths R; Jones R; Vasudev N; Wheater M; Hamid A; Waddell T; McMenemin R; Patel P; Larkin J; Faust G; Martin A; Swain J; Bestall J; McCabe C; Meads D; Goh V; Min Wah T; Brown J; Hewison J; Selby P; Collinson F;
Lancet Oncol; 2023 Mar; 24(3):213-227. PubMed ID: 36796394
[TBL] [Abstract] [Full Text] [Related]
6. Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma.
Gubbi S; Al-Jundi M; Del Rivero J; Jha A; Knue M; Zou J; Turkbey B; Carrasquillo JA; Lin E; Pacak K; Klubo-Gwiezdzinska J; Lin FI
Front Endocrinol (Lausanne); 2020; 11():587065. PubMed ID: 33551992
[TBL] [Abstract] [Full Text] [Related]
7. Improving survival prediction using a novel feature selection and feature reduction framework based on the integration of clinical and molecular data.
Neums L; Meier R; Koestler DC; Thompson JA
Pac Symp Biocomput; 2020; 25():415-426. PubMed ID: 31797615
[TBL] [Abstract] [Full Text] [Related]
8. [Comparison of operative and oncologic results between partial nephrectomy and radiofrequency ablation for treatment of renal tumors in patients older than 75].
Cholley I; Correas JM; Masson-Lecomte A; Sanchez S; Champy C; Le Guilchet T; Ariane M; Hurel S; Audenet F; Thiounn N; Fontaine E; Mejean A; Timsit MO
Prog Urol; 2018 Jan; 28(1):55-61. PubMed ID: 29174691
[TBL] [Abstract] [Full Text] [Related]
9. Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma.
Lee JY; Song C; Hong BS; Hong JH; Ahn H; Lee JL
Cancer Chemother Pharmacol; 2017 Jan; 79(1):173-180. PubMed ID: 28011979
[TBL] [Abstract] [Full Text] [Related]
10. Use of metformin and risk of kidney cancer in patients with type 2 diabetes.
Tseng CH
Eur J Cancer; 2016 Jan; 52():19-25. PubMed ID: 26630530
[TBL] [Abstract] [Full Text] [Related]
11. Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis.
Iacovelli R; Sternberg CN; Porta C; Verzoni E; de Braud F; Escudier B; Procopio G
Curr Drug Targets; 2015; 16(2):164-70. PubMed ID: 25410406
[TBL] [Abstract] [Full Text] [Related]
12. [Surgical treatment of bone metastases from renal cell carcinoma].
Wang H; Zhou N; Xu X; Zhai J; Zhu X; Li G; Wang J; Liu N; He F; Wang H; Huang G; Man L
Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(4):289-92. PubMed ID: 24731497
[TBL] [Abstract] [Full Text] [Related]
13. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.
Heng DY; Xie W; Regan MM; Harshman LC; Bjarnason GA; Vaishampayan UN; Mackenzie M; Wood L; Donskov F; Tan MH; Rha SY; Agarwal N; Kollmannsberger C; Rini BI; Choueiri TK
Lancet Oncol; 2013 Feb; 14(2):141-8. PubMed ID: 23312463
[TBL] [Abstract] [Full Text] [Related]
14. Phaseolus beans: impact on glycaemic response and chronic disease risk in human subjects.
Hutchins AM; Winham DM; Thompson SV
Br J Nutr; 2012 Aug; 108 Suppl 1():S52-65. PubMed ID: 22916816
[TBL] [Abstract] [Full Text] [Related]
15. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
Jensen SA; Sørensen JB
Cancer Chemother Pharmacol; 2006 Oct; 58(4):487-93. PubMed ID: 16418875
[TBL] [Abstract] [Full Text] [Related]
16. [The condition of long-term survivors and patients cured of childhood neoplasms].
Gutjahr P
Fortschr Med; 1980 Feb; 98(8):289-92. PubMed ID: 6247258
[TBL] [Abstract] [Full Text] [Related]
17. Radiographic manifestations of bone metastases from renal carcinoma.
Forbes GS; McLeod RA; Hattery RR
AJR Am J Roentgenol; 1977 Jul; 129(1):61-6. PubMed ID: 409145
[TBL] [Abstract] [Full Text] [Related]
